IL2 and arthritic joint disease: Increased resolution of clinical activity was observed in multiple disease manifestations in patients receiving LD-IL-2 treatment, including thrombocytopenia (2 of 4 [50.0%]), leukopenia (4 of 12 [33.3%]) and arthritis (10 of 10 [100%]), and persistent parotid gland swelling (9 of 12 [66.7%]) (Table 2 and eTable 6 in Supplement 2).